C4X Discovery Holdings plc, of Manchester, U.K., and GTN Ltd., of London, are collaborating to discover small-molecule candidates against an undisclosed neurodegeneration target. C4XD will contribute its conformational analysis platform, Conformetrix, and GTN will add its in silico discovery platform. Terms of the deal weren't disclosed.